{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T10:59:03Z","timestamp":1781089143405,"version":"3.54.1"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neuroimmune Pharmacol"],"DOI":"10.1007\/s11481-026-10296-9","type":"journal-article","created":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T08:52:14Z","timestamp":1781081534000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Natural Killer Cells: Dual Regulators and Therapeutic Targets in Multiple Sclerosis Immunopathogenesis"],"prefix":"10.1007","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9815-2365","authenticated-orcid":false,"given":"Maryam Vahdat","family":"Lasemi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2442-0635","authenticated-orcid":false,"given":"Maryam","family":"Mehravar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9852-1821","authenticated-orcid":false,"given":"Amirhossein","family":"Izadpanah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorsa","family":"Halvachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7846-3222","authenticated-orcid":false,"given":"Sahar","family":"Parkhideh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-0149-3516","authenticated-orcid":false,"given":"Hoda","family":"Hasheminasab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2711-9277","authenticated-orcid":false,"given":"Abbas","family":"Hajifathali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3698-4342","authenticated-orcid":false,"given":"Elham","family":"Roshandel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,10]]},"reference":[{"key":"10296_CR1","doi-asserted-by":"publisher","first-page":"1500770","DOI":"10.3389\/fncel.2025.1500770","volume":"19","author":"F Aghaee","year":"2025","unstructured":"Aghaee F, Abedinpour M, Anvari S, Saberi A, Fallah A, Bakhshi A (2025) Natural killer cells in multiple sclerosis: foe or friends? Front Cell Neurosci 19:1500770","journal-title":"Front Cell Neurosci"},{"key":"10296_CR2","doi-asserted-by":"publisher","first-page":"1101379","DOI":"10.3389\/fncel.2023.1101379","volume":"17","author":"G Angelini","year":"2023","unstructured":"Angelini G, Bani A, Constantin G, Rossi B (2023) The interplay between T helper cells and brain barriers in the pathogenesis of multiple sclerosis. Front Cell Neurosci 17:1101379","journal-title":"Front Cell Neurosci"},{"key":"10296_CR3","doi-asserted-by":"crossref","unstructured":"Cantoni C, Smirnov RA, Firulyova M, Andhey PS, Bradstreet TR, Esaulova E, Wu GF (2025) A single-cell compendium of human cerebrospinal fluid identifies disease-associated immune cell populations. J Clin Investig, 135(1)","DOI":"10.1172\/JCI177793"},{"issue":"1","key":"10296_CR4","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1038\/s41392-024-02005-w","volume":"9","author":"S Chen","year":"2024","unstructured":"Chen S, Zhu H, Jounaidi Y (2024) Comprehensive snapshots of natural killer cells functions, signaling, molecular mechanisms and clinical utilization. Signal Transduct Target Therapy 9(1):302","journal-title":"Signal Transduct Target Therapy"},{"key":"10296_CR5","doi-asserted-by":"publisher","first-page":"1595533","DOI":"10.3389\/fimmu.2025.1595533","volume":"16","author":"M Chen","year":"2025","unstructured":"Chen M, Zhang B, Mu X, Zhang B, Yang T, Zhang G, Liang S (2025) Recent advances in tumor immunotherapy based on NK cells. Front Immunol 16:1595533","journal-title":"Front Immunol"},{"issue":"10","key":"10296_CR6","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1084\/jem.20141678","volume":"212","author":"WP Chong","year":"2015","unstructured":"Chong WP, van Panhuys N, Chen J, Silver PB, Jittayasothorn Y, Mattapallil MJ, Caspi RR (2015) NK-DC crosstalk controls the autopathogenic Th17 response through an innate IFN-\u03b3\u2013IL-27 axis. J Exp Med 212(10):1739\u20131752","journal-title":"J Exp Med"},{"issue":"18","key":"10296_CR7","doi-asserted-by":"publisher","first-page":"9765","DOI":"10.3390\/ijms22189765","volume":"22","author":"Y Chun","year":"2021","unstructured":"Chun Y, Kim J (2021) AMPK\u2013mTOR signaling and cellular adaptations in hypoxia. Int J Mol Sci 22(18):9765","journal-title":"Int J Mol Sci"},{"issue":"12","key":"10296_CR8","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.4049\/jimmunol.2300834","volume":"212","author":"DC Chung","year":"2024","unstructured":"Chung DC, Garcia-Batres CR, Millar DG, Wong SW, Elford AR, Mathews JA, Clarke BA (2024) Generation of an inhibitory NK cell subset by TGF-\u03b21\/IL-15 polarization. J Immunol 212(12):1904\u20131912","journal-title":"J Immunol"},{"issue":"4","key":"10296_CR9","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1111\/j.1476-5381.2011.01302.x","volume":"164","author":"CS Constantinescu","year":"2011","unstructured":"Constantinescu CS, Farooqi N, O\u2019Brien K, Gran B (2011) Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS). Br J Pharmacol 164(4):1079\u20131106","journal-title":"Br J Pharmacol"},{"issue":"9","key":"10296_CR10","doi-asserted-by":"publisher","first-page":"4477","DOI":"10.4049\/jimmunol.1401558","volume":"193","author":"RP Donnelly","year":"2014","unstructured":"Donnelly RP, Loftus RM, Keating SE, Liou KT, Biron CA, Gardiner CM, Finlay DK (2014) MTORC1-dependent metabolic reprogramming is a prerequisite for NK cell effector function. J Immunol 193(9):4477\u20134484","journal-title":"J Immunol"},{"issue":"4","key":"10296_CR11","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1111\/imm.12012","volume":"137","author":"PF Durrenberger","year":"2012","unstructured":"Durrenberger PF, Webb LV, Sim MJ, Nicholas RS, Altmann DM, Boyton RJ (2012) Increased HLA-E expression in white matter lesions in multiple sclerosis. Immunology 137(4):317\u2013325","journal-title":"Immunology"},{"issue":"5","key":"10296_CR12","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1097\/CJI.0b013e3181d372a0","volume":"33","author":"K Edsparr","year":"2010","unstructured":"Edsparr K, Speetjens FM, Mulder-Stapel A, Goldfarb RH, Basse PH, Lennern\u00e4s B, Albertsson P (2010) Effects of IL-2 on MMP expression in freshly isolated human NK cells and the IL-2-independent NK cell line YT. J Immunother 33(5):475\u2013481","journal-title":"J Immunother"},{"issue":"6","key":"10296_CR13","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1177\/1753425916658111","volume":"22","author":"M Gao","year":"2016","unstructured":"Gao M, Yang Y, Li D, Ming B, Chen H, Sun Y, Zheng F (2016) CD27 natural killer cell subsets play different roles during the pre-onset stage of experimental autoimmune encephalomyelitis. Innate Immun 22(6):395\u2013404","journal-title":"Innate Immun"},{"key":"10296_CR14","doi-asserted-by":"publisher","first-page":"606","DOI":"10.3389\/fimmu.2016.00606","volume":"7","author":"CC Gross","year":"2016","unstructured":"Gross CC, Schulte-Mecklenbeck A, Wiendl H, Marcenaro E, Kerlero de Rosbo N, Uccelli A, Laroni A (2016) Regulatory functions of natural killer cells in multiple sclerosis. Front Immunol 7:606","journal-title":"Front Immunol"},{"key":"10296_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.817473","volume":"13","author":"AH Heng","year":"2022","unstructured":"Heng AH, Han CW, Abbott C, McColl SR, Comerford I (2022) Chemokine-driven migration of pro-inflammatory CD4\u2009+\u2009T cells in CNS autoimmune disease. Front Immunol 13:817473","journal-title":"Front Immunol"},{"issue":"1","key":"10296_CR16","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1111\/imr.13314","volume":"323","author":"L Hermans","year":"2024","unstructured":"Hermans L, O\u2019Sullivan TE (2024) No time to die: epigenetic regulation of natural killer cell survival. Immunol Rev 323(1):61\u201379","journal-title":"Immunol Rev"},{"issue":"8","key":"10296_CR17","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1002\/eji.201546194","volume":"46","author":"L Hertwig","year":"2016","unstructured":"Hertwig L, Hamann I, Romero-Suarez S, Millward JM, Pietrek R, Chanvillard C, Cardona AE (2016) CX3CR1\u2010dependent recruitment of mature NK cells into the central nervous system contributes to control autoimmune neuroinflammation. Eur J Immunol 46(8):1984\u20131996","journal-title":"Eur J Immunol"},{"key":"10296_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1275028","volume":"14","author":"H Jiang","year":"2023","unstructured":"Jiang H, Jiang J (2023) Balancing act: the complex role of NK cells in immune regulation. Front Immunol 14:1275028","journal-title":"Front Immunol"},{"issue":"2","key":"10296_CR19","doi-asserted-by":"publisher","first-page":"781","DOI":"10.4049\/jimmunol.1100789","volume":"187","author":"W Jiang","year":"2011","unstructured":"Jiang W, Chai NR, Maric D, Bielekova B (2011) Unexpected role for granzyme K in CD56bright NK cell-mediated immunoregulation of multiple sclerosis. J Immunol 187(2):781\u2013790","journal-title":"J Immunol"},{"key":"10296_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1442694","volume":"15","author":"X Jiang","year":"2024","unstructured":"Jiang X, Zhang H, Liu Y, Sun B, Mu G (2024) Global perspectives on the contribution of B cells to multiple sclerosis: an in-depth examination and evaluation. Front Immunol 15:1442694","journal-title":"Front Immunol"},{"issue":"1","key":"10296_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-025-00633-8","volume":"14","author":"LV J\u00f8rgensen","year":"2025","unstructured":"J\u00f8rgensen LV, Christensen EB, Barnkob MB, Barington T (2025) The clinical landscape of CAR NK cells. Exp Hematol Oncol 14(1):46","journal-title":"Exp Hematol Oncol"},{"issue":"2","key":"10296_CR22","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.3390\/curroncol28020105","volume":"28","author":"S Kang","year":"2021","unstructured":"Kang S, Gao X, Zhang L, Yang E, Li Y, Yu L (2021) The advances and challenges of NK cell-based cancer immunotherapy. Curr Oncol 28(2):1077\u20131093","journal-title":"Curr Oncol"},{"issue":"9","key":"10296_CR23","doi-asserted-by":"publisher","first-page":"2657","DOI":"10.1093\/brain\/aws159","volume":"136","author":"G Kaur","year":"2013","unstructured":"Kaur G, Trowsdale J, Fugger L (2013) Natural killer cells and their receptors in multiple sclerosis. Brain 136(9):2657\u20132676","journal-title":"Brain"},{"issue":"11","key":"10296_CR24","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.3390\/v16111746","volume":"16","author":"J Koki\u00e7i","year":"2024","unstructured":"Koki\u00e7i J, Preechanukul A, Arellano-Ballestero H, Gorou F, Peppa D (2024) Emerging Insights into Memory Natural Killer Cells and Clinical Applications. Viruses 16(11):1746","journal-title":"Viruses"},{"key":"10296_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.622306","volume":"12","author":"UC Kucuksezer","year":"2021","unstructured":"Kucuksezer UC, Aktas Cetin E, Esen F, Tahrali I, Akdeniz N, Gelmez MY, Deniz G (2021) The role of natural killer cells in autoimmune diseases. Front Immunol 12:622306","journal-title":"Front Immunol"},{"issue":"5","key":"10296_CR26","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.3390\/jcm9051450","volume":"9","author":"A Laroni","year":"2020","unstructured":"Laroni A, Uccelli A (2020) CD56bright natural killer cells: a possible biomarker of different treatments in multiple sclerosis. J Clin Med 9(5):1450","journal-title":"J Clin Med"},{"issue":"1","key":"10296_CR27","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1111\/imr.13031","volume":"305","author":"CM Lau","year":"2022","unstructured":"Lau CM, Wiedemann GM, Sun JC (2022) Epigenetic regulation of natural killer cell memory. Immunol Rev 305(1):90\u2013110","journal-title":"Immunol Rev"},{"key":"10296_CR28","doi-asserted-by":"publisher","first-page":"996469","DOI":"10.3389\/fimmu.2022.996469","volume":"13","author":"R Liu","year":"2022","unstructured":"Liu R, Du S, Zhao L, Jain S, Sahay K, Rizvanov A, Khaiboullina S (2022) Autoreactive lymphocytes in multiple sclerosis: Pathogenesis and treatment target. Front Immunol 13:996469","journal-title":"Front Immunol"},{"key":"10296_CR29","doi-asserted-by":"crossref","unstructured":"L\u00f3pez-Botet M, De Maria A, Muntasell A, Della Chiesa M, Vilches C (2023) Adaptive NK cell response to human cytomegalovirus: Facts and open issues. Paper presented at the Seminars in immunology","DOI":"10.1016\/j.smim.2022.101706"},{"issue":"9","key":"10296_CR30","doi-asserted-by":"publisher","first-page":"6170","DOI":"10.4049\/jimmunol.181.9.6170","volume":"181","author":"A Lunemann","year":"2008","unstructured":"Lunemann A, Lunemann JD, Roberts S, Messmer B, da Silva RB, Raine CS, Munz C (2008) Human NK cells kill resting but not activated microglia via NKG2D-and NKp46-mediated recognition. J Immunol 181(9):6170\u20136177","journal-title":"J Immunol"},{"issue":"2","key":"10296_CR31","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1093\/intimm\/dxq463","volume":"23","author":"A L\u00fcnemann","year":"2011","unstructured":"L\u00fcnemann A, Tackenberg B, DeAngelis T, da Silva B, Messmer R, Vanoaica B, L\u00fcnemann LD, J. D (2011) Impaired IFN-\u03b3 production and proliferation of NK cells in multiple sclerosis. Int Immunol 23(2):139\u2013148","journal-title":"Int Immunol"},{"issue":"1","key":"10296_CR32","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/s41467-020-20594-2","volume":"12","author":"EF McKinney","year":"2021","unstructured":"McKinney EF, Cuthbertson I, Harris KM, Smilek DE, Connor C, Manferrari G, Smith KG (2021) A CD8\u2009+\u2009NK cell transcriptomic signature associated with clinical outcome in relapsing remitting multiple sclerosis. Nat Commun 12(1):635","journal-title":"Nat Commun"},{"issue":"1","key":"10296_CR33","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1186\/s12967-024-05033-w","volume":"22","author":"L Miao","year":"2024","unstructured":"Miao L, Lu C, Zhang B, Li H, Zhao X, Chen H, Cui X (2024) Advances in metabolic reprogramming of NK cells in the tumor microenvironment on the impact of NK therapy. J Translational Med 22(1):229","journal-title":"J Translational Med"},{"key":"10296_CR34","unstructured":"Mimpen MC (2022) Circulating lymphocyte subsets as prognostic markers in multiple sclerosis. a first step towards systems immunology"},{"issue":"3","key":"10296_CR35","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1111\/ene.14680","volume":"28","author":"M Mimpen","year":"2021","unstructured":"Mimpen M, Muris AH, Rolf L, Gerlach O, Kuhle J, Hupperts R, Damoiseaux J (2021) Prognostic value of natural killer cell\/T cell ratios for disease activity in multiple sclerosis. Eur J Neurol 28(3):901\u2013909","journal-title":"Eur J Neurol"},{"key":"10296_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2023.216121","volume":"559","author":"B Moran","year":"2023","unstructured":"Moran B, Davern M, Reynolds JV, Donlon NE, Lysaght J (2023) The impact of histone deacetylase inhibitors on immune cells and implications for cancer therapy. Cancer Lett 559:216121","journal-title":"Cancer Lett"},{"key":"10296_CR37","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.3389\/fimmu.2019.02403","volume":"10","author":"A Moreira","year":"2019","unstructured":"Moreira A, Alari-Pahissa E, Munteis E, Vera A, Zabalza A, Llop M, Villar LM (2019) Adaptive features of natural killer cells in multiple sclerosis. Front Immunol 10:2403","journal-title":"Front Immunol"},{"key":"10296_CR38","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1269614","volume":"14","author":"S Nersesian","year":"2023","unstructured":"Nersesian S, Carter EB, Lee SN, Westhaver LP, Boudreau JE (2023) Killer instincts: natural killer cells as multifactorial cancer immunotherapy. Front Immunol 14:1269614","journal-title":"Front Immunol"},{"issue":"1","key":"10296_CR39","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-023-01324-9","volume":"21","author":"Z Ning","year":"2023","unstructured":"Ning Z, Liu Y, Guo D, Lin W-J, Tang Y (2023) Natural killer cells in the central nervous system. Cell Commun Signal 21(1):341","journal-title":"Cell Commun Signal"},{"issue":"2","key":"10296_CR40","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.3390\/cimb45020094","volume":"45","author":"G Papiri","year":"2023","unstructured":"Papiri G, D\u2019Andreamatteo G, Cacchi\u00f2 G, Alia S, Silvestrini M, Paci C, Vignini A (2023) Multiple sclerosis: inflammatory and neuroglial aspects. Curr Issues Mol Biol 45(2):1443\u20131470","journal-title":"Curr Issues Mol Biol"},{"issue":"4","key":"10296_CR41","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1111\/j.1365-2567.2008.03027.x","volume":"126","author":"A Poli","year":"2009","unstructured":"Poli A, Michel T, Th\u00e9r\u00e9sine M, Andr\u00e8s E, Hentges F, Zimmer J (2009) CD56bright natural killer (NK) cells: an important NK cell subset. Immunology 126(4):458\u2013465","journal-title":"Immunology"},{"key":"10296_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2024.100977","author":"E Portaccio","year":"2024","unstructured":"Portaccio E, Magyari M, Havrdova EK, Ruet A, Brochet B, Scalfari A, Di Filippo M, Tur C, Montalban X, Amato MP (2024) Multiple sclerosis: emerging epidemiological trends and redefining the clinical course. Lancet Reg Health Eur. https:\/\/doi.org\/10.1016\/j.lanepe.2024.100977","journal-title":"Lancet Reg Health Eur"},{"key":"10296_CR43","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1540263","volume":"16","author":"C Prado","year":"2025","unstructured":"Prado C, Herrada AA, Hevia D, Goiry LG, Escobedo N (2025) Role of innate immune cells in multiple sclerosis. Front Immunol 16:1540263","journal-title":"Front Immunol"},{"issue":"7","key":"10296_CR44","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1002\/eji.202049028","volume":"51","author":"L Quatrini","year":"2021","unstructured":"Quatrini L, Della Chiesa M, Sivori S, Mingari MC, Pende D, Moretta L (2021) Human NK cells, their receptors and function. Eur J Immunol 51(7):1566\u20131579","journal-title":"Eur J Immunol"},{"key":"10296_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2025.06.006","author":"S Rana","year":"2025","unstructured":"Rana S, Thomas L, Kirkham AM, Shorr R, Visram A, Maganti H, Seftel M, Allan DS (2025) CAR-NK cells to treat patients with cancer: a systematic scoping review of published studies and registered clinical trials. Cytotherapy. https:\/\/doi.org\/10.1016\/j.jcyt.2025.06.006","journal-title":"Cytotherapy"},{"key":"10296_CR46","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00311","volume":"11","author":"S Regis","year":"2020","unstructured":"Regis S, Dondero A, Caliendo F, Bottino C, Castriconi R (2020) NK cell function regulation by TGF-\u03b2-induced epigenetic mechanisms. Front Immunol 11:311","journal-title":"Front Immunol"},{"issue":"2","key":"10296_CR47","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s13760-024-02488-y","volume":"124","author":"I Rodrigues Barreto","year":"2024","unstructured":"Rodrigues Barreto I, Monteiro A, Paiva A, Fonseca AM (2024) Relapsing\u2013remitting multiple sclerosis patients exhibit differential natural killer functional subpopulations. Acta Neurol Belg 124(2):603\u2013610","journal-title":"Acta Neurol Belg"},{"key":"10296_CR48","doi-asserted-by":"publisher","first-page":"e73849","DOI":"10.7554\/eLife.73849","volume":"11","author":"S Rodr\u00edguez-Lorenzo","year":"2022","unstructured":"Rodr\u00edguez-Lorenzo S, van Olst L, Rodriguez-Mogeda C, Kamermans A, van der Pol SM, Rodr\u00edguez E, de Vries HE (2022) Single-cell profiling reveals periventricular CD56bright NK cell accumulation in multiple sclerosis. Elife 11:e73849","journal-title":"Elife"},{"issue":"2","key":"10296_CR49","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1111\/cei.12580","volume":"180","author":"E Rodr\u00edguez-Mart\u00edn","year":"2015","unstructured":"Rodr\u00edguez-Mart\u00edn E, Pic\u00f3n C, Costa-Frossard L, Alenda R, Sainz De La Maza S, Rold\u00e1n E, \u00c1lvarez-Cerme\u00f1o JC (2015) Natural killer cell subsets in cerebrospinal fluid of patients with multiple sclerosis. Clin Exp Immunol 180(2):243\u2013249","journal-title":"Clin Exp Immunol"},{"issue":"1","key":"10296_CR50","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-024-03040-8","volume":"21","author":"C Rodriguez-Mogeda","year":"2024","unstructured":"Rodriguez-Mogeda C, van Ansenwoude CM, van der Molen L, Strijbis EM, Mebius RE, de Vries HE (2024) The role of CD56bright NK cells in neurodegenerative disorders. J Neuroinflammation 21(1):48","journal-title":"J Neuroinflammation"},{"issue":"3","key":"10296_CR51","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s10072-007-0803-3","volume":"28","author":"M Saraste","year":"2007","unstructured":"Saraste M, Irjala H, Airas L (2007) Expansion of CD56bright natural killer cells in the peripheral blood of multiple sclerosis patients treated with interferon-beta. Neurol Sci 28(3):121\u2013126","journal-title":"Neurol Sci"},{"issue":"1","key":"10296_CR52","doi-asserted-by":"publisher","first-page":"e00020","DOI":"10.1097\/IN9.0000000000000020","volume":"5","author":"H Sohn","year":"2023","unstructured":"Sohn H, Cooper MA (2023) Metabolic regulation of NK cell function: implications for immunotherapy. Immunometabolism 5(1):e00020","journal-title":"Immunometabolism"},{"issue":"1","key":"10296_CR53","doi-asserted-by":"publisher","first-page":"4","DOI":"10.37349\/eemd.2023.00002","volume":"1","author":"C Steenblock","year":"2024","unstructured":"Steenblock C, Eitler J, Oikonomakos IT, Arriens M, K\u00fcnzel SR, Tonn T, Bornstein SR (2024) Application of chimeric antigen receptor-natural killer cells for the treatment of type 1 diabetes. Explor Endoc Metab Dis 1(1):4\u201311","journal-title":"Explor Endoc Metab Dis"},{"key":"10296_CR54","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1073971","volume":"13","author":"Y-Y Tang","year":"2023","unstructured":"Tang Y-Y, Wang D-C, Wang Y-Q, Huang A-F, Xu W-D (2023) Emerging role of hypoxia-inducible factor-1\u03b1 in inflammatory autoimmune diseases: a comprehensive review. Front Immunol 13:1073971","journal-title":"Front Immunol"},{"issue":"6","key":"10296_CR55","doi-asserted-by":"publisher","first-page":"e010822","DOI":"10.1136\/jitc-2024-010822","volume":"13","author":"X Wang","year":"2025","unstructured":"Wang X, Luo W, Chen Z, Li C, Zhou J, Huang Z, Li Y (2025a) Co-expression of IL-15 and CCL21 strengthens CAR-NK cells to eliminate tumors in concert with T cells and equips them with PI3K\/AKT\/mTOR signal signature. J Immunother Cancer 13(6):e010822","journal-title":"J Immunother Cancer"},{"key":"10296_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2025.05.038","author":"X Wang","year":"2025","unstructured":"Wang X, Zhang Y, Jin Y, Dai L, Yue Y, Hu J, Liu X, Pang K, Ye S, Ye W, Shi X, Ma X, Guo L, Liu Y, Ta N, Zhu X, Lin L, Wang J, Yan R, Wang P, Song X, Zhou Y, Zhou L, Wang Q, Guan T, Li T, Pan W, He Y, Wu X, Xu Y, Yang L, Xu H, Chen Y (2025b) An iPSC-derived CD19\/BCMA CAR-NK therapy in a patient with systemic sclerosis. Cell. https:\/\/doi.org\/10.1016\/j.cell.2025.05.038","journal-title":"Cell"},{"issue":"2","key":"10296_CR57","first-page":"239","volume":"1812","author":"MS Weber","year":"2011","unstructured":"Weber MS, Hemmer B, Cepok S (2011) The role of antibodies in multiple sclerosis. Biochim et Biophys Acta (BBA)-Molecular Basis Disease 1812(2):239\u2013245","journal-title":"Biochim et Biophys Acta (BBA)-Molecular Basis Disease"},{"key":"10296_CR58","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.913054","volume":"13","author":"GM Wiedemann","year":"2022","unstructured":"Wiedemann GM (2022) Localization matters: epigenetic regulation of natural killer cells in different tissue microenvironments. Front Immunol 13:913054","journal-title":"Front Immunol"},{"key":"10296_CR59","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.672328","volume":"12","author":"M Xia","year":"2021","unstructured":"Xia M, Wang B, Wang Z, Zhang X, Wang X (2021) Epigenetic regulation of NK cell-mediated antitumor immunity. Front Immunol 12:672328","journal-title":"Front Immunol"},{"issue":"21","key":"10296_CR60","doi-asserted-by":"publisher","first-page":"3534","DOI":"10.1016\/j.neuron.2022.06.023","volume":"110","author":"VW Yong","year":"2022","unstructured":"Yong VW (2022) Microglia in multiple sclerosis: Protectors turn destroyers. Neuron 110(21):3534\u20133548","journal-title":"Neuron"},{"key":"10296_CR61","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.116371","volume":"173","author":"Q Zhang","year":"2024","unstructured":"Zhang Q, Lin J, Yang M, Li Z, Zhang M, Bu B (2024) Therapeutic potential of natural killer cells in neuroimmunological diseases. Biomed Pharmacother 173:116371","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"10296_CR62","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/S1474-4422(23)00377-0","volume":"23","author":"B Zierfuss","year":"2024","unstructured":"Zierfuss B, Larochelle C, Prat A (2024) Blood\u2013brain barrier dysfunction in multiple sclerosis: causes, consequences, and potential effects of therapies. Lancet Neurol 23(1):95\u2013109","journal-title":"Lancet Neurol"},{"key":"10296_CR63","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00025","volume":"8","author":"NW Zwirner","year":"2017","unstructured":"Zwirner NW, Ziblat A (2017) Regulation of NK cell activation and effector functions by the IL-12 family of cytokines: the case of IL-27. Front Immunol 8:25","journal-title":"Front Immunol"}],"container-title":["Journal of Neuroimmune Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11481-026-10296-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11481-026-10296-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11481-026-10296-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T10:02:27Z","timestamp":1781085747000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11481-026-10296-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,10]]},"references-count":63,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["10296"],"URL":"https:\/\/doi.org\/10.1007\/s11481-026-10296-9","relation":{},"ISSN":["1557-1904"],"issn-type":[{"value":"1557-1904","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,10]]},"assertion":[{"value":"29 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"28"}}